4/8/2013

Aastrom Biosciences has started recruiting patients for a Phase IIb trial that will assess the safety and efficacy of its experimental drug Ixmyelocel-T in
people with advanced heart failure due to ischemic dilated cardiomyopathy. The randomized, double-blind trial will involve 108 patients.

Related Summaries